Winton Group’s Acorda Therapeutics ACOR Stock Holding History

Winton Group’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,084	Closed	-$265K	–	1581
2019 Q4	$265K	Buy	+1,084	New	+$274K	﹤0.01%	1392

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Winton Group's ACOR Position: Q1 2020 in Review

Winton Group sold out of Acorda Therapeutics (ACOR) in Q1 2020, closing a stake of 1,084 shares — an estimated $265K sold.

Winton Group first reported a position in ACOR in Q4 2019 and held it in 1 quarter. The position peaked at $265K in Q4 2019. 106 funds tracked by Wall St. Rank hold ACOR as of Q1 2020.

Winton Group reported no remaining Acorda Therapeutics position as of Q1 2020 after selling out during the quarter.
Winton Group sold 1,084 Acorda Therapeutics shares in Q1 2020, an estimated $265K.
Winton Group first reported a position in Acorda Therapeutics in Q4 2019 and held it in 1 quarter.
Winton Group's Acorda Therapeutics position peaked at $265K in Q4 2019.
106 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2020.

Based on Winton Group's 13F filing for Q1 2020, filed 11 May 2020.